Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-13 of 13 for your search:
Cancer Type/Condition:
Myelodysplastic/myeloproliferative diseases
Trial Type:
Treatment
Treatment/Intervention:
Stem Cell Transplantation, bone marrow ablation with stem cell support, bone marrow therapy, allogeneic
Trial Status:
Active
Trial Phase:
Phase III
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase II/III Study of Standard and Novel Conditioning Therapy Followed By Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 to 70
Sponsor:
Other
Protocol IDs:
RPCI-RP-9815
, NCI-V99-1527, NCT00003816, RP 98-15
2.
Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT)
Phase:
Phase III, Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
Levosta-CBF-02/04
, NCT00215007
3.
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
12 to 55
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GC P#02.01.001
, NCT00469729
4.
Stem Cell Transplant for Hematological Malignancy
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
54 and under
Sponsor:
Other
Protocol IDs:
0107M05202
, MT2001-02, NCT00176930
5.
Phase III Randomized Study of Myeloablative Versus Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
65 and under
Sponsor:
NCI, NHLBI
Protocol IDs:
FHCRC-1992.00
, 6170, NCT00322101, NHLBI-K23-HL084054-01A1
6.
A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-Risk Haematology Patients
Phase:
Phase III
Type:
Diagnostic, Treatment
Status:
Active
Age:
18 to 80
Sponsor:
Other
Protocol IDs:
55/05
, ALLG SC01, NHMRC Project Grant 331305, NCT00163722
7.
Phase III Randomized Study of Filgrastim (G-CSF)-Mobilized Matched-Sibling Donor Peripheral Blood Stem Cell Transplantation Versus G-CSF-Stimulated Matched-Sibling Donor Bone Marrow Transplantation in Patients With Hematologic Malignancies or Other Diseases
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
16 to 65
Sponsor:
NCI
Protocol IDs:
CBMTG-0601
, NCT00438958
8.
Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
12 to 65
Sponsor:
Other
Protocol IDs:
PROGAST
, NCT00180089
9.
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
SCT 0307
, NCT00619879
10.
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD)
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
2 to 55
Sponsor:
NCI, NHLBI
Protocol IDs:
385
, BMT CTN 0402, U01 HL069294-05, NCT00406393
11.
Dose-Reduced Versus Standard Conditioning Prior Allo SCT for MDS/sAML Patients
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
RICMAC
, EBMT 42205525, NCT00682396
12.
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
MC-FludT.14/L
, EudraCT-No.: 2008-002356-18, NCT00822393
13.
Randomized Allogeneic Azacitidine Study
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
2008-0503
, NCT00887068
Select All on Page
Help with Results
